Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RORC | P51449 | 3/20 | 0.61 |
| ▸ | DRD2 | P14416 | 1/20 | 0.44 |
| ▸ | DRD3 | P35462 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.43 |
| ▸ | BCHE | P06276 | 2/20 | 0.42 |
| ▸ | ACHE | P22303 | 2/20 | 0.42 |
| ▸ | BACE1 | P56817 | 2/20 | 0.42 |
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | CCR5 | P51681 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 2/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5452654 | 1.00 | RORC (0.61) | RORCDRD2DRD3ALDH1A1MAPK1 | |
| SCHEMBL5452662 | 1.00 | RORC (0.61) | RORCDRD2DRD3ALDH1A1MAPK1 | |
| SCHEMBL29129081 | 1.00 | RORC (0.61) | RORCDRD2DRD3ALDH1A1MAPK1 | |
| SCHEMBL13229947 | 0.91 | CCR5 (0.48) | RORCDRD2DRD3ALDH1A1KDM4E | |
| SCHEMBL1202294 | 0.91 | CCR5 (0.48) | RORCDRD2DRD3ALDH1A1KDM4E | |
| SCHEMBL1202290 | 0.91 | CCR5 (0.48) | RORCDRD2DRD3ALDH1A1KDM4E | |
| SCHEMBL16965290 | 0.91 | CCR5 (0.48) | RORCDRD2DRD3ALDH1A1KDM4E | |
| SCHEMBL1977480 | 0.88 | RORC (0.46) | RORCDRD2DRD3ALDH1A1MAPK1 | |
| SCHEMBL1202867 | 0.88 | RORC (0.46) | RORCDRD2DRD3ALDH1A1MAPK1 | |
| SCHEMBL2800422 | 0.88 | RORC (0.46) | RORCDRD2DRD3ALDH1A1MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117279636-A | Methods and compounds for modulating myotonic muscular dystrophy type 1 | 设计治疗公司 | 2023-12-22 | — | — | CN | disclosed |
| WO-2021195183-A1 | COMPOSITIONS AND METHODS FOR INHIBITING PROTEIN EMBRYONIC ECTODERM DEVELOPMENT ACTIVITY AND TREATING DISEASE | EXO THERAPEUTICS, INC. (US) | 2021-09-30 | — | — | WO | disclosed |
| US-9957274-B2 | Indane inhibitors of EED and methods of their use | ABBVIE INC. (US) | 2018-05-01 | — | — | US | disclosed |
| US-20170320880-A1 | INDANE INHIBITORS OF EED AND METHODS OF THEIR USE | ABBVIE INC. | 2017-11-09 | — | — | US | disclosed |
| US-20070270471-A1 | Compounds Which Potentiate Glutamate Receptor and Uses Thereof in Medicine | GLAXO GROUP LIMITED (GB) | 2007-11-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170320880-A1 | INDANE INHIBITORS OF EED AND METHODS OF THEIR USE | EEF1D, ECI1, EED | RORC 420/4885DRD2 1281/4885DRD3 1294/4885 |
| US-20070270471-A1 | Compounds Which Potentiate Glutamate Receptor and Uses Thereof in Medicine | GRM3, GLRA3, GLRA1 | RORC 932/4885DRD2 271/4885DRD3 228/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.